Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators

Saint Luke's Health System

Overview

This study is intended to assess the effects of astaxanthin use on pain, physical function, and inflammation as reflected by Patient-Reported Outcomes Measurement Information System (PROMIS) scores and levels of inflammatory biomarkers in subjects taking astaxanthin. If improvements in pain, function, and/or markers of inflammation could be demonstrated with the use of astaxanthin, this may suggest the potential for astaxanthin to be used in management of knee osteoarthritis (and possibly other forms of osteoarthritis) with less evident toxicity than seen with the presently available standard therapies (e.g. NSAIDS, opioids).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Conditions

Osteoarthritis, Knee

Interventions

astaxanthinDIETARY_SUPPLEMENT

astaxanthin capsules 12 mg twice daily

PlaceboOTHER

placebo capsules twice daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or older * Symptoms of knee pain * Radiographic evidence of mild to moderate arthritis * Able to provide written consent on their own behalf Exclusion Criteria: * Pregnancy * Current tobacco use * Current substance abuse (alcohol or drug) * Presence of significant cardiovascular, pulmonary, hepatic, or renal disease * Prior history of knee trauma or surgery * Gout or pseudogout * Significant depression or anxiety scores on PHQ-9 and GAD-7, or pre-existing diagnosis of a significant mental health disorder * Presence of other chronic pain syndromes such as chronic low back or neck pain, fibromyalgia, or complex regional pain syndrome * Presence of systemic inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease * Symptomatic involvement of multiple other joints with osteoarthritis * Known allergy to fish or astaxanthin * BMI greater than 35 * Participation in another clinical trial

Locations (1)

Saint Luke's Hospital of Kansas City

Kansas City, Missouri, United States

Outcomes

Primary Outcomes

Change in PROMIS Numeric Rating Pain Scale

Pain improvement in subjects is the primary outcome measure. The Patient Reported Outcomes Measurement Information Systems (PROMIS) Pain Intensity Scale 1a tool will be used. This scale ranges from 0-10, with 0 representing no pain and 10 representing the worst pain imaginable.

Time frame: 20 weeks

Secondary Outcomes

Change in PROMIS Pain interference score

Reduction in pain interference is a secondary outcome measure. The Patient Reported Outcomes Measurement Information Systems (PROMIS) Pain Interference Short Form 6b will be used as the survey tool for pain interference. This is a set of 6 questions to assess the degree to which pain has interfered with daily activities. There are 5 levels of pain interference from 0 (none at all) to 5 (very much or always). The higher the score, the greater the pain interference.

Time frame: 20 weeks

Change in PROMIS Physical function score

Improvement in physical function is a secondary outcome measure. The PROMIS Physical Function Short Form 6b will be used as the survey tool for physical limitation. There are 5 levels of limitation to physical function from 0 (without any difficulty) to 5 (unable to do). The higher the score, the greater the limitation

Time frame: 20 weeks

Change in Erythrocyte Sedimentation Rate

Change in ESR (mm/hr)

Time frame: 20 weeks

Change in C-reactive protein levels

Change in CRP levels (mg/L)

Time frame: 20 weeks

Change in Interleukin-6 levels

Change in IL-6 levels (pg/mL)

Time frame: 20 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.